| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PYY3 |
| Uniprot No | Q5JQD4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-70aa |
| 氨基酸序列 | ALVDTCP IKPEAPGEDE SLEELSHYYA SLCHYLNVVT RQWWEGADMW |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PYY3-36重组蛋白的参考文献示例(部分信息为示例性概括，实际文献可能需要进一步验证)：
---
1. **文献名称**：*"Recombinant PYY3-36 production in Escherichia coli: Optimization and therapeutic potential in appetite regulation"*
**作者**：Zhang, L. et al.
**摘要**：本研究报道了利用大肠杆菌表达系统高效生产重组PYY3-36蛋白的工艺优化，通过密码子优化和纯化策略改进，获得高纯度活性蛋白。动物实验表明，重组PYY3-36可显著抑制食欲，提示其在肥胖治疗中的应用潜力。
2. **文献名称**：*"Pharmacokinetic enhancement of PEGylated recombinant PYY3-36 for sustained anti-obesity effects"*
**作者**：Chen, Y. et al.
**摘要**：通过聚乙二醇(PEG)修饰重组PYY3-36蛋白，显著延长其半衰期并提高稳定性。药效学实验显示，修饰后的蛋白在小鼠模型中持续抑制摄食并减轻体重，为长效制剂开发提供依据。
3. **文献名称**：*"Central and peripheral effects of recombinant PYY3-36 on glucose homeostasis in diabetic models"*
**作者**：Batterham, R.L. et al.
**摘要**：探讨重组PYY3-36对2型糖尿病模型血糖调控的双重作用，发现其通过激活下丘脑神经元和外周Y2受体通路，改善胰岛素敏感性和葡萄糖代谢，提示代谢疾病治疗新靶点。
4. **文献名称**：*"Design of a stable PYY3-36 analog with enhanced receptor selectivity and oral bioavailability"*
**作者**：Liu, W. et al.
**摘要**：通过氨基酸替换和结构修饰，设计出具有更高Y2受体选择性和口服生物利用度的PYY3-36类似物。体外和体内实验证实其显著抗肥胖活性，为口服制剂开发奠定基础。
---
**注**：以上文献为示例性内容，实际引用时建议通过数据库(如PubMed、Web of Science)检索最新研究，并核对作者、标题及摘要准确性。
**Background of Recombinant PYY3-36 Protein**
Peptide YY (PYY), a 36-amino acid gut hormone, belongs to the neuropeptide Y (NPY) family and is primarily secreted by intestinal L-cells postprandially. PYY exists in two major forms: PYY1-36 (full-length) and PYY3-36 (active truncated form), with the latter generated by dipeptidyl peptidase-4 (DPP-4)-mediated cleavage. PYY3-36 exerts its effects via the Y2 receptor (Y2R), a G protein-coupled receptor highly expressed in the hypothalamus and peripheral tissues.
Physiologically, PYY3-36 is a key regulator of appetite and energy homeostasis. It inhibits food intake by modulating neural circuits in the brainstem and hypothalamus, particularly by suppressing NPY/AgRP neurons and activating pro-opiomelanocortin (POMC) neurons. This anorexigenic effect has positioned PYY3-36 as a potential therapeutic target for obesity and metabolic disorders.
Recombinant PYY3-36 is produced using biotechnological platforms, such as *E. coli* or mammalian expression systems, ensuring high purity and bioactivity. Its therapeutic applications are under investigation, including use in weight management, diabetes, and gastrointestinal motility disorders. Preclinical and clinical studies demonstrate its ability to reduce caloric intake and improve glycemic control, though challenges like short half-life and delivery methods remain.
Research continues to explore engineered analogs and sustained-release formulations to enhance clinical efficacy. Overall, recombinant PYY3-36 represents a promising biologic bridging gut-brain signaling and metabolic disease therapeutics.
(Word count: 199)
×
